Maravai LifeSciences Holdings, Inc. (MRVI) vs Recursion Pharmaceuticals, Inc. (RXRX)
A side-by-side comparison of Maravai LifeSciences Holdings, Inc. and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MRVI
Maravai LifeSciences Holdings, Inc.
$7.85HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RXRX
Recursion Pharmaceuticals, Inc.
$4.63HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — MRVI vs RXRX
growth of $100 · dividends reinvested · last 5yMRVI -76.7% (-25.3%/yr)RXRX -73.4% (-23.3%/yr)RXRX compounded faster over this window
MRVI RXRX
MRVI vs RXRX: by the numbers
- •RXRX is the larger company ($2.43B vs $2.17B market cap).
- •Both run net losses; MRVI's is the smaller (-37.07% vs -945.92% net margin).
- •RXRX grew revenue faster over the past five years (45.50% vs -17.68% CAGR).
Metrics side by side
Valuation
| Metric | MRVI | RXRX |
|---|---|---|
| P/S ratio | 10.39 | 44.29 |
| P/B ratio | 10.60 | 2.65 |
| EV / EBITDA | 15.02 | N/A |
Profitability
| Metric | MRVI | RXRX |
|---|---|---|
| Gross margin | 17.98% | -61.96% |
| Operating margin | -3.63% | -867.87% |
| Net margin | -37.07% | -945.92% |
| ROE | -37.82% | -56.71% |
| ROIC | 16.96% | -49.78% |
Growth (annualized)
| Metric | MRVI | RXRX |
|---|---|---|
| Revenue CAGR (5Y) | -17.68% | 45.50% |
| Total return CAGR (5Y) | -27.63% | -25.86% |
Frequently asked
- Which has grown faster, MRVI or RXRX?
- Over the past five years, RXRX grew revenue faster — MRVI at a -17.68% CAGR versus RXRX at 45.50%.
- How have MRVI and RXRX total returns compared?
- Over the past 5 years, MRVI delivered -27.63% and RXRX delivered -25.86% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Maravai LifeSciences ROERecursion Pharmaceuticals ROEMaravai LifeSciences operating marginRecursion Pharmaceuticals operating marginMaravai LifeSciences revenue growthRecursion Pharmaceuticals revenue growthMaravai LifeSciences free cash flowRecursion Pharmaceuticals free cash flow
Maravai LifeSciences & Recursion Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.